ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0156

Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database

Brinda Basida1, Sanket Basida2, Jasleen Kaur3, Urja Nagadia2, mahmoud mansour2, Palak Shah4 and Monil Majmundar5, 1DMC/Sinai Grace Hospital, Detroit, MI, 2University of Missouri, Columbia, MO, 3DMC/WSU, Saginaw, MI, 4Metropolitan Hospital Center, New York Medical College, New York, NY, 5University of Kansas Medical Center, Kansas City, KS

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, dermatomyositis, Myopathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Muscle Biology, Myositis and Myopathies Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are systemic autoimmune diseases of inflammatory infiltrates in skeletal muscle resulting in chronic muscle weakness. Systemic involvement of the lungs, esophagus, and heart is seen in patients with PM/DM. Cardiac complications in these patients have been demonstrated as a poor prognostic factor in previous studies. Most patients and physicians ignore these cardiac complications due to the lack of symptoms in the early stages. [1] Our study aims to analyze the impact of PM/DM on the in-hospital outcomes of patients with Congestive Heart Failure (CHF).

Methods: All adult hospitalized patients from January 2016 to December 2019 in the nationwide inpatient sample (NIS) were captured. The study population included all patients with a primary diagnosis of CHF using ICD-10 codes (International Classification of Diseases, tenth edition). We then identified patients with a secondary diagnosis of PM or DM. The CHF population was divided into patients with PM/DM (study) and without PM/DM (control). We used Wilcoxon rank sum test for comparing continuous variables and Chi-square tests for categorical variables. For univariate and multivariate analysis, we performed univariate and multivariate logistic regression models respectively. The primary outcome was mortality rates and secondary outcomes were morbidity rates and healthcare utilization.

Results: The sample size included 4,815,134 patients admitted for CHF, of which 99.95% did not have underlying PM/DM, while 0.05% did. 70.69% of patients in the study group were female and were relatively younger, with a mean age of 66 years vs. 71 years in the control group (p< 0.001). There was a higher mortality rate (4.47%) in those with PM/DM compared to those without it (2.65%) (adjusted OR=2.01, p< 0.003). There was a higher incidence of Cardiogenic shock in the study group. Still, the rate of Acute respiratory failure and need for mechanical ventilation were not statistically different between the two groups. The adjusted mean total hospitalization charge was $14,275 higher (p< 0.04), and the adjusted mean length of stay was 1.03 days higher (< 0.002) in group 2 compared to group 1.

Conclusion: Polymyositis/Dermatomyositis increases mortality by two-fold in CHF patients. It is also associated with increased cost and length of hospital stay, thus increasing the burden on patients and healthcare. Since there is no testing apart from the auxiliary examinations that are excellent in sensitivity and specificity to determine cardiac complications in its early stages, it is vital to pay more attention to the cardiac examination in PM/DM.

Supporting image 1

Table_1 In-Hospital outcomes and healthcare utilization in patients with congestive heart failure

Supporting image 2

Figure_1 Impact of Polymyositis/Dermatomyositis on congestive heart failure outcomes


Disclosures: B. Basida, None; S. Basida, None; J. Kaur, None; U. Nagadia, None; m. mansour, None; P. Shah, None; M. Majmundar, None.

To cite this abstract in AMA style:

Basida B, Basida S, Kaur J, Nagadia U, mansour m, Shah P, Majmundar M. Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-polymyositis-and-dermatomyositis-in-patients-admitted-with-congestive-heart-failure-an-insight-from-the-national-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-polymyositis-and-dermatomyositis-in-patients-admitted-with-congestive-heart-failure-an-insight-from-the-national-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology